GAT Therapeutics
GAT Therapeutics is an early stage biopharma targeting orphan fibrotic diseases.
GTX-11 is a novel TGF-β pathway modulator. We believe it has the potential to become mainstay therapy for orphan fibrotic diseases.
Foundation date